Gilead Sciences, Inc. which can be found using ticker (GILD) now have 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $121.00 and $69.00 calculating the mean target share price we have $85.04. (at the time of writing). Now with the previous closing price of $73.98 this would imply there is now a potential upside of 14.9%. Also worth taking note is the 50 day moving average now sits at $76.45 while the 200 day moving average is $77.34. The company has a market cap of 91.05B. The stock price for the company is currently $73.09 USD
The potential market cap would be $104,665,786,315 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 16.24, revenue per share of $21.73 and a 9.78% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
